Catalyst Dossier · compiled by CeliA 🧫

Ipsen Biopharmaceuticals, Inc. (IPSEY)

Healthcare · market cap $15.0B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Ipsen Biopharmaceuticals (IPSEY) is a mid-cap specialty healthcare company with approximately 5,358 employees and a market capitalization of roughly $15 billion. The company fields a broad pipeline spanning rare diseases, oncology, neuroscience, and endocrinology, with key near-term catalysts centered on elafibranor in Primary Biliary Cholangitis, odevixibat in Biliary Atresia, and multiple IPN10200 readouts through 2027. The most imminent catalyst is a Phase 3 elafibranor data point estimated for June 26, 2026.

The catalyst path

2026-08-31 (est.)Phase 2 · Dysportimp 7/10
2026-10-26 (est.)Phase 2 · Cabozantinibimp 7/10
2026-12-15 (est.)Phase 3 · IPN10200imp 9/10
2027-01-31 (est.)Phase 2 · IPN10200 dose Aimp 7/10
2027-03-26 (est.)Phase 2 · IPN10200imp 7/10
2027-05-31 (est.)Phase 2 · IPN10200 dose Aimp 7/10
2027-05-31 (est.)Phase 2 · IPN10200imp 7/10

Pipeline

Asset	Phase	Indication
EGb761®	Phase 2	Alzheimer's Disease
Lanreotide Autogel®	Phase 3	Acromegaly
Lanreotide (Autogel formulation)	Phase 3	Acromegaly
Odevixibat	Phase 3	Biliary Atresia
Lanreotide PRF	Phase 2	Acromegaly
IPN01195	Phase 2	Advanced Solid Tumor
nal-IRI	Phase 2	Pancreatic Cancer
IPN60300	Phase 2	Locally Advanced Solid Tumor
Triptorelin pamoate (embonate) salt	Phase 3	Advanced Prostate Cancer
Elafibranor	Phase 3	Primary Biliary Cholangitis
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval	Phase 3	Acromegaly
Triptorelin Pamoate (Pamorelin® LA 11.25 mg)	Phase 2	Prostate Cancer
BN83495	Phase 2	Endometrial Cancer
Triptorelin pamoate 11.25mg (Decapeptyl® SR)	Phase 3	Precocious Puberty
Botulinum toxin type A	Phase 3	Glabellar Frown Lines
Triptorelin (I.N.N.)	Phase 3	Precocious Puberty
EGb761	Phase 3	Stroke, Acute
mecasermin	Phase 3	Growth Hormone Insensitivity Syndrome
Eziclen	Phase 3	Bowel Cleansing
rhIGF-1 (mecasermin) for a period of 86 weeks	Phase 3	Insulin-Like Growth Factor-1 Deficiency

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IPSEY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.